DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/qp3s33/investigation) has announced the addition of the "Investigation Report on China Insulin Detemir Market, 2010-2019" report to their offering.
Insulin Detemir, a new long-acting soluble (avoiding the common side effects of non-solvent insulin) human insulin analogue, was made by Novo Nordisk through energetic engineering. It came into the American market in 2005 and brought in sales revenue of USD 2 billion around the world in 2014.
According to CRI's market survey, insulin detemir develops fast after entering China in 2009, annual sales rising from less than CNY 3 million in 2010 to CNY 68 million in 2014 and CAGR during this period reaching up to 135%. Currently, insulin detemir market in China is monopolized by Novo Nordisk. The price range of 300 IU 3 ML insulin determir (one injection per package) in Chinese sample hospitals is CNY 193-205/package and there is little difference between citites.
Key Topics Covered:
1 Related Concepts of Insulin Detemir
2 Market Profile of Insulin Detemir in China
3 Survey on Sales Value of Insulin Detemir in China, 2010-2014
4 Survey on Sales Volume of Insulin Detemir in China, 2010-2014
5 Survey on Market Share of Major Manufacturers of Insulin Detemir in China, 2010-2014
6 Survey on Market Size of Dosage Forms of Insulin Detemir in China, 2010-2014
7 Reference Price of Insulin Detemir in Chinese Hospitals in 2013
8 Major Manufacturers of Insulin Detemir in Chinese Market, 2010-2014
9 Market Outlook of Insulin Detemir in China, 2014-2018
- Novo Nordisk
For more information visit http://www.researchandmarkets.com/research/qp3s33/investigation